A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants

With Moderate to Severe Hidradenitis Suppurativa


ID #NCT04242498

Recruitment Status: recruiting as of August 2020


Estimated Completion Date: May of 2023

Sponsors and Collaborators: UCB Biopharma SRL

Information provided by (Responsible Party): UCB Biopharma SRL

Brief Summary: The purpose of the study is to test the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS).

Please link for complete details https://clinicaltrials.gov/ct2/show/NCT04242498

Locations: multiple locations please refer to link above for further information.

Contact: UCB Cares 1844599 ext 2273 UCBCares@ucb.com


© 2021 by HS Connect, LLC  |  HSConnect.org@gmail.com  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579